Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:31:55.586Z.
Calculation as of: 2026-10-06T21:31:55.586Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4936500bc1589ca9a686c77de910b68cd28581e4c5f82a550ef1f7d6df46dce9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Evogene Ltd.
Market Cap
$3.65M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Evogene Ltd. (EVGN) | $3.65M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.65M | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.50M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.90M | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
